Clinical Trial Update: Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety and activity of lenvatinib (E7080) in KIF5B-RET–positive adenocarcinoma of the lung has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Lung Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: KIF5B-RET-Positive Adenocarcinoma of the Lung | Phase 2 | Status: COMPLETED | Results posted: 2019-08-13